Cellectar Biosciences Goodwill and Intangible Assets 2010-2025 | CLRB
Cellectar Biosciences goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
| Cellectar Biosciences Annual Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $0 |
| 2017 | $2 |
| 2016 | $2 |
| 2015 | $2 |
| 2014 | $2 |
| 2013 | $2 |
| 2012 | $2 |
| 2011 | $2 |
| 2010 | $0 |
| 2009 | $0 |
| Cellectar Biosciences Quarterly Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2025-06-30 | |
| 2025-03-31 | |
| 2024-12-31 | |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | $2 |
| 2018-06-30 | $2 |
| 2018-03-31 | $2 |
| 2017-12-31 | $2 |
| 2017-09-30 | $2 |
| 2017-06-30 | $2 |
| 2017-03-31 | $2 |
| 2016-12-31 | $2 |
| 2016-09-30 | $2 |
| 2016-06-30 | $2 |
| 2016-03-31 | $2 |
| 2015-12-31 | $2 |
| 2015-09-30 | $2 |
| 2015-06-30 | $2 |
| 2015-03-31 | $2 |
| 2014-12-31 | $2 |
| 2014-09-30 | $2 |
| 2014-06-30 | $2 |
| 2014-03-31 | $2 |
| 2013-12-31 | $2 |
| 2013-09-30 | $2 |
| 2013-06-30 | $2 |
| 2013-03-31 | $2 |
| 2012-12-31 | $2 |
| 2012-09-30 | $2 |
| 2012-06-30 | $2 |
| 2012-03-31 | $2 |
| 2011-12-31 | $2 |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | |
| 2010-09-30 | $0 |
| 2010-06-30 | $0 |
| 2010-03-31 | $0 |
| 2009-12-31 | $0 |
| 2009-09-30 | $0 |
| 2009-06-30 | $0 |
| 2009-03-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.015B | $0.000B |
| Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. | |||